Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy

Current Medical Research and Opinion
Loay KassemOmar Abdel-Rahman

Abstract

A major, yet precisely studied, shift has occurred in the treatment of advanced hormone-sensitive prostate cancer (HSPC) by the addition of docetaxel to androgen deprivation therapy (ADT) in the first line. Recently, two landmark trials showed that abiraterone acetate (AA) can be an effective alternative along with ADT in the same setting. We implemented a network meta-analysis to compare the safety and efficacy of the two combinations. PubMed database, ASCO and ESMO meeting library databases of all results published until June 2017 were searched using the keywords: "prostate cancer" AND "docetaxel" OR "abiraterone acetate". Efficacy endpoints including progression-free survival (PFS) and overall survival (OS), and safety endpoints (including treatment related deaths and selected adverse events) were assessed. Twenty relevant studies were retrieved and assessed for eligibility. Of those trials, eight were found potentially eligible. Inconsistent reporting of efficacy outcomes limited our analysis to M1 HSPC. The pooled hazard ratios (HRs) of OS and PFS of the direct comparison of abiraterone acetate plus ADT versus ADT were 0.63 (95% CI: 0.545-0.717) and 0.38 (95% CI: 0.34-0.43), respectively. Meanwhile, in the trials of doceta...Continue Reading

References

Jan 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V HugJ Clark
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Nov 29, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Karim FizaziStephane Culine
Dec 12, 2012·The New England Journal of Medicine·Charles J RyanUNKNOWN COU-AA-302 Investigators
Dec 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elahe A MostaghelBruce Montgomery
Feb 18, 2014·Cancer Research·Irene RomeroAngel M Garcia-Lora
Oct 15, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary-Ellen TaplinPhilip W Kantoff
Aug 6, 2015·The New England Journal of Medicine·Christopher J SweeneyRobert S DiPaola
Jun 6, 2017·The New England Journal of Medicine·Karim FizaziUNKNOWN LATITUDE Investigators
Jun 6, 2017·The New England Journal of Medicine·Nicholas D JamesUNKNOWN STAMPEDE Investigators

❮ Previous
Next ❯

Citations

Jun 1, 2019·The New England Journal of Medicine·Kim N ChiUNKNOWN TITAN Investigators
Jul 30, 2019·Expert Opinion on Drug Safety·Pietro CastellanLuca Cindolo
Nov 13, 2019·European Journal of Pharmacology·Sebastian StudentRafał Bułdak
Dec 18, 2020·International Journal of Molecular Sciences·Fabrizio FontanaPatrizia Limonta
Dec 2, 2020·International Journal of Clinical Practice·Amit BahlHeather Payne

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.